Specific issues of using modern anticoagulants for prescribing thromboembolic complications during surgical interventions

Thromboembolic complications are among the most dangerous and, unfortunately, the most common lethal complications of elective surgical interventions. Today, anticoagulant therapy plays a leading role in preventing their occurrence in everyday clinical practice. A significant increase in the number of comorbid patients with the need for anticoagulant therapy for the prevention or treatment of venous thromboembolic complications requires surgeons to be aware of the specific issues of prescribing and/or discontinuing modern anticoagulant drugs. Today, low-molecular-weight heparins are the drugs of choice for routine prevention and long-term treatment of thrombotic complications. Traditionally, medical professionals consider these drugs similar and interchangeable, but they differ significantly in terms of their relative antithrombin activity, indications and contraindications in specific clinical situations, and the principles of dose adjustment. Currently, most patients requiring elective surgical interventions require a personalized approach to anticoagulant therapy.